New Market Research Report: Taiwan Pharmaceuticals & Healthcare Report Q4 2015

From: Fast Market Research, Inc.
Published: Mon Aug 31 2015

Taiwan will remain a key destination for clinical trials due to the government's efforts to augment the country's medical infrastructure and streamline clinical research regulatory processes. In addition, there will be further upsides to the clinical trials sector should Taiwan be able to successfully harmonise its regulations with China and allow for the mutual recognition of data.

Headline Expenditure Projections

Pharmaceuticals: TWD167.7bn (USD5.5bn) in 2014 to TWD175.1bn (USD5.6bn) in 2015; +4.4% in local currency terms and +0.5% in US dollar terms. Unchanged from previous quarter.

Full Report Details at

Healthcare: TWD1,005.4bn (USD33.2bn) in 2014 to TWD1,046.8bn (USD33.2bn) in 2015; +4.1% in local currency terms and +0.3% in US dollar terms. Forecast maintained from previous quarter.

Risk/Reward Index

Taiwan ranks fourth out of the 19 key markets with a score at 64.9 for Q415 in our Risk/Reward Index, edging ahead of Hong Kong in the Asia Pacific region in terms of attractiveness. Key to the country's high score is its high market expenditure at TWD167bn (USD5.5bn) which scores 14.0 out of 20.0, above the regional average of 10.6. However, this is dragged down by the sector's growth (scoring 6.0 out of 12.0, below the regional average of 6.5) as authorities look towards cost containment measures including medicine price cuts to control rising healthcare spending.

Key Trends and Developments

For the month of August 2015, Taiwan's Health Promotion Administration urged patients diagnosed with cancer to get treatment immediately. According to authorities, 18% of all cancer patients in the country do not get treatment within three months of their diagnosis. This resulted in a 53% one-year mortality rate as compared with 17% among those who sought treatment immediately.

In July 2015, the Common Health Magazine disclosed the results of a survey which suggested that 52% of the public were willing to pay TWD10 (USD0.3) to TWD100 (USD3.1) more health insurance.

The Taiwan Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Taiwan Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Taiwan pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for Taiwan, to test other views - a key input for successful budgeting and strategic business planning in the Taiwanese pharmaceutical and healthcare market.
* Target business opportunities and risks in the Taiwanese pharmaceutical and healthcare sector

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Bahrain Pharmaceuticals & Healthcare Report Q4 2015
- Romania Pharmaceuticals & Healthcare Report Q4 2015
- Bulgaria Pharmaceuticals & Healthcare Report Q4 2015
- Peru Pharmaceuticals & Healthcare Report Q4 2015
- Latvia Pharmaceuticals & Healthcare Report Q4 2015

Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email:
Contact Phone: 1-413-485-7001

Visit website »